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To the Editor
Among diabetics on hemodialysis (HD), there are conflicting data as to whether
thiazolidinedione (TZD) use improves or worsens survival.1, 2 Ramirez et al. compared
rosiglitazone and pioglitazone with non-TZD oral hypoglycemic agents and found 38%
higher all-cause mortality and 59% higher cardiovascular mortality among rosiglitazone
users, although no differences were seen for pioglitazone.1 In contrast, Brunelli et al.
compared any TZD use with non-users and found 53% lower all-cause mortality among
non-insulin users who used TZDs; no significant difference was seen among insulin users.2
Recent data in the general type 2 diabetic population have shown better survival among
incident rosiglitazone versus glipizide users.3 However, data from the general population
may not apply to dialysis patients because of unique physiological circumstances, greater
burden of illness among dialysis patients, and competing risks. We conducted this study to
evaluate the comparative effectiveness of TZD use versus sulfonylurea (SU) use with
respect to mortality among hemodialysis patients.
Methods
Data for this retrospective study were obtained from a randomly selected cohort of 14,643
prevalent adult patients receiving thrice-weekly in-center hemodialysis in one of 1247
facilities operated by a large US dialysis organization between 1-1-2005 and 1-16-2009. We
identified 608 patients with incident use of TZD or SU during the study period. Use of a
TZD or SU was taken as evidence that these patients were diabetic. Incident use was defined
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as a new prescription, which started after a period of at least 90 days during which the
patient was dialyzed at the clinic and was not receiving either medication. Incident TZD
users were matched (1:n) with replacement to incident SU users on the basis of insulin use
and on a propensity score based on age, sex, race, dry weight, catheter use, heart failure, and
serum albumin.4, 5 Patients were considered at-risk for the outcome of all-cause mortality
immediately after the start of the new TZD or SU prescription and remained at risk until
death, transfer of care, transplant, or end of study (2-21-2009). Standardized differences
were used to compare matched groups; standardized difference >10% (or <-10%) signifies
substantive imbalance.6 Associations with mortality were estimated using Cox proportional
hazard models. All analyses were performed using Stata 12 (StataCorp LP, College Station,
TX). This study was deemed exempt by the Partners Healthcare Institutional Review Board.
Results
In the unmatched cohort, unadjusted Kaplan-Meier survival curves show an association
between improved survival and TZD use when compared to SU use (Figure). Overall, 230
incident TZD users were matched to 434 incident SU users (94 TZD to 168 SU on insulin;
136 TZD to 266 SU not on insulin). Cumulative at-risk time was 966 patient-years; 207
deaths occurred. Baseline characteristics of TZD and matched SU users are presented in the
Table; the two groups were similar in terms of all variables studied except that TZD users
were more likely to have pre-existing liver disease and on average had a shorter dialysis
vintage. Incident TZD users had a significantly lower risk of death: HR (95% CI) 0.70
(0.53–0.92). In contrast to the unadjusted analysis, there was suggestion of effect
modification based on concurrent insulin status (p-interaction=0.06): HRs (95% CIs) for
TZD versus SU were 0.57 (0.40–0.82) among patients not on insulin, and 0.99 (0.63–1.55)
among insulin users.
Comments
For diabetics on HD, TZD use versus SU use was associated with 30% lower all-cause
mortality. These findings are similar to the results obtained by Brunelli et al., which showed
TZD use versus non-use was associated with lower mortality among non-insulin dependent
diabetics, but no difference in mortality among insulin users. The present analysis suggested
similar effect modification by insulin, however this finding should be interpreted carefully
because it (narrowly) missed formal levels of statistical significance. In contrast, Ramirez et
al. found that rosiglitazone users had greater mortality compared to patients using other oral
hypoglycemic agents. Our study differs from prior studies in that it was limited to new users
of TZD and SUs. New user designs are preferable for studies of comparative effectiveness
because they enable appropriate adjustment for patient characteristics at the time treatment
decisions were rendered. Also, results are not subject to bias due to differential survival that
may have occurred after initial exposure to medication and prior to the period of observation
(eg, depletion of susceptibles).7 The precise mechanism by which TZDs may improve
mortality is not well elucidated, but data indicate that TZD use may decrease catabolism by
improving insulin sensitivity8 and mitigate cardiovascular risk profiles.9, 10 Despite the use
of statistical methods to minimize confounding, residual confounding may still exist;
however, the residual differences that were observed (more liver disease and earlier dialysis
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vintage) should bias against TZDs, which would render our estimates conservative.
Prospective studies are needed to confirm these results.
In conclusion, among diabetics on HD, incident TZD use versus SU use was associated with
30% lower all-cause mortality. This effect may be limited to patients not concurrently on
insulin.
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Figure.
Kaplan-Meier survival curves showing the association between survival and incident TZD
treatment compared to incident SU treatment when stratified on insulin use in the unmatched
cohort.
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Table
Baseline comparison of incident TZD users and matched incident SU users.*
SU use (N=434) TZD use (N=230) Standardized difference
Age (years) a,b 64.9 +/− 11.8 64.2 +/− 11.4 −0.052
Female a 48.2% 51.3% 0.063
Black a 35.5% 33.9% −0.033
Dry weight (kg) a,b 80.1 +/− 21.5 78.6 +/− 24.4 −0.065
Catheter use a,b 21.9% 23.9% 0.048
Heart failure a 22.1% 19.1% −0.073
Albumin (g/dL) a,b 3.8 +/− 0.4 3.8 +/− 0.4 −0.007
Use of insulin b,c 38.7% 40.9% 0.044
Dialysis vintage (m) b 3.8 +/− 2.8 3.2 +/− 2.1 −0.213
Vascular disease b 4.8% 4.4% −0.023
Hyperlipidemia b 20.3% 21.7% 0.036
Cancer b 1.6% 2.6% 0.072
Liver disease b 0.7% 3.0% 0.194
Creatinine (mg/dL) b 7.9 +/− 2.6 8.0 +/− 2.6 0.017
Phosphorus (mg/dL) b 5.3 +/− 1.6 5.2 +/− 1.6 −0.052
Corrected calcium (mg/dL) b 9.4 +/− 0.7 9.4 +/− 0.7 −0.035
Ln(Ferritin) (ln(ng/mL)) b 6.23 +/− 0.66 6.20 +/− 0.69 −0.056
Hemoglobin (g/dL) b 12.1 +/− 1.4 12.1 +/− 1.5 −0.027
Use of other oral diabetic medications b 4.8% 3.9% −0.045
aVariable considered in propensity score.
bConsidered as of the time of incident TZD/SU use.
cGroups were matched on this independently of propensity score.
*
Data presented as mean +/− SD or n (%).
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